Synergistic Activity of ALK and STAT3 Inhibitors for the Treatment of ALK Mutated Neuroblastoma Cells

被引：0
|
作者：
Hiwatari, M. [1 ]
Watanabe, K. [2 ]
Kimura, S. [2 ]
Takita, J. [2 ]
机构：
[1] Univ Tokyo, Cell Therapy & Transplantat Med, Tokyo, Japan
[2] Univ Tokyo, Pediat, Tokyo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO-354
引用
收藏
页码：S252 / S252
页数：1
相关论文
共 50 条
  • [41] Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells
    Uchihara, Yuki
    Komori, Reiko
    Tago, Kenji
    Tamura, Hiroomi
    Funakoshi-Tago, Megumi
    BIOCHEMICAL PHARMACOLOGY, 2019, 170
  • [42] Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma
    Khoury, JD
    Medeiros, LJ
    Rassidakis, GZ
    Yared, MA
    Tsioli, P
    Leventaki, V
    Schmitt-Graeff, A
    Herling, M
    Amin, HM
    Lai, R
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3692 - 3699
  • [43] Novel TENM3–ALK fusion is an alternate mechanism for ALK activation in neuroblastoma
    Mitsuteru Hiwatari
    Masafumi Seki
    Ryosuke Matsuno
    Kenichi Yoshida
    Takeshi Nagasawa
    Aiko Sato-Otsubo
    Shohei Yamamoto
    Motohiro Kato
    Kentaro Watanabe
    Masahiro Sekiguchi
    Satoru Miyano
    Seishi Ogawa
    Junko Takita
    Oncogene, 2022, 41 : 2789 - 2797
  • [44] Stat3 and Ras activation are required for the cellular transformation mediated by NPM-ALK
    Chiarle, R
    Guasparri, I
    Zamo, A
    Raz, R
    Levy, DE
    Inghirami, G
    MODERN PATHOLOGY, 2001, 14 (01) : 159A - 159A
  • [45] Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
    Roberto Chiarle
    William J Simmons
    Honjying Cai
    Girish Dhall
    Alberto Zamo
    Regina Raz
    James G Karras
    David E Levy
    Giorgio Inghirami
    Nature Medicine, 2005, 11 : 623 - 629
  • [46] Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
    Chiarle, R
    Simmons, WJ
    Cai, HY
    Dhall, G
    Zamo', A
    Raz, R
    Karras, JG
    Levy, DE
    Inghirami, G
    NATURE MEDICINE, 2005, 11 (06) : 623 - 629
  • [47] Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma
    Hiwatari, Mitsuteru
    Seki, Masafumi
    Matsuno, Ryosuke
    Yoshida, Kenichi
    Nagasawa, Takeshi
    Sato-Otsubo, Aiko
    Yamamoto, Shohei
    Kato, Motohiro
    Watanabe, Kentaro
    Sekiguchi, Masahiro
    Miyano, Satoru
    Ogawa, Seishi
    Takita, Junko
    ONCOGENE, 2022, 41 (20) : 2789 - 2797
  • [48] Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
    Moore, Nathan F.
    Azarova, Anna M.
    Bhatnagar, Namrata
    Ross, Kenneth N.
    Drake, Lauren E.
    Frumm, Stacey
    Liu, Qinsong S.
    Christie, Amanda L.
    Sanda, Takaomi
    Chesler, Louis
    Kung, Andrew L.
    Gray, Nathanael S.
    Stegmaier, Kimberly
    George, Rani E.
    ONCOTARGET, 2014, 5 (18) : 8737 - 8749
  • [49] Stat3 and Ras activation are required for the cellular transformation mediated by NPM-ALK
    Chiarle, R
    Guasparri, I
    Zamo, A
    Raz, R
    Levy, DE
    Inghirami, G
    LABORATORY INVESTIGATION, 2001, 81 (01) : 159A - 159A
  • [50] Inhibition of Axl improves the targeted therapy against ALK-mutated neuroblastoma
    Xu, Fei
    Li, Hongling
    Sun, Yong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2014, 454 (04) : 566 - 571
12345